Who Paid My Doc
Byron Hutchinson
Podiatrist Burien, WA Doctor of Podiatric Medicine
NPI 1730130592 CMS profile 213953
16233 Sylvester Rd #G10, Highline Foot Ankle Clinic, Burien, WA 98166
General payments
$903,158
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$10,232
Through program year 2025, Byron Hutchinson of Burien, WA is reported in the CMS Open Payments database as having received $903,158 across 380 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,232 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $130,360 | 48 | |
| 2024 | General | $161,079 | 43 | |
| 2023 | General | $237,126 | 62 | |
| 2022 | General | $159,568 | 76 | |
| 2021 | General | $108,848 | 58 | |
| 2020 | General | $29,064 | 17 | |
| 2019 | General | $77,112 | 76 |
Beside peers
- Byron Hutchinson
- Podiatrist median
- Middle half of Podiatrist
- National median
In program year 2025, general payments to Byron Hutchinson were reported at $130,360. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.
Show as a table
| Year | Byron Hutchinson | Podiatrist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $77,112 | $196 | $72–$601 | $163 |
| 2020 | $29,064 | $118 | $38–$335 | $114 |
| 2021 | $108,848 | $169 | $57–$573 | $132 |
| 2022 | $159,568 | $220 | $74–$782 | $149 |
| 2023 | $237,126 | $208 | $71–$635 | $160 |
| 2024 | $161,079 | $237 | $87–$681 | $164 |
| 2025 | $130,360 | $260 | $94–$777 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$3,817
Medicare patients
16
Services billed
95
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 69% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
380 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Podiatrist in Washington
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist
Everyone recorded under this specialty, nationwide.
Doctors in Washington
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.